Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186550 · ClinicalTrials.gov registry record · NA
Group Psychotherapy for People With HIV
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 186
- Enrollment target
NCT00186550: Completed NA study, sponsored by Stanford University.
NCT00186550 is a NA study that has completed, run by Stanford University. The registered enrollment target is 186 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186550, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 186 participants
- Enrollment target
Study Summary
This study will examine the effectiveness of supportive-expressive group therapy plus education compared with an educational intervention in improving the quality of life and promoting health-enhancing behavior of men and women living with HIV or AIDS.
Interventions
- BEHAVIORAL Education
- BEHAVIORAL Supportive Expressive Group Psychotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Est. Completion | 2000-11 |
| Phase | NA |
What the finished NCT00186550 record still lists
NCT00186550 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Education is the first listed.
NCT00186550 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00186550 about?
NCT00186550 is a clinical study titled "Group Psychotherapy for People With HIV". This study will examine the effectiveness of supportive-expressive group therapy plus education compared with an educational intervention in improving the quality of life and promoting health-enhancing behavior of men and women living with HIV or AIDS.
What is the current status of trial NCT00186550?
This trial is currently completed. It is a NA study. The enrollment target is 186 participants. Estimated completion is 2000-11.
What interventions are being tested in trial NCT00186550?
The interventions under investigation include: Education (BEHAVIORAL), Supportive Expressive Group Psychotherapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00186550?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00186550's enrollment target sits among peer trials
186 579th of 2000 higher than 1,421 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes